SiBone (NASDAQ:SIBN) Insider Sells $47,181.75 in Stock

SiBone (NASDAQ:SIBN) insider Anthony Recupero sold 3,311 shares of the company’s stock in a transaction that occurred on Thursday, October 2nd. The shares were sold at an average price of $14.25, for a total value of $47,181.75. Following the transaction, the insider directly owned 271,977 shares of the company’s stock, valued at $3,875,672.25. The trade was a 1.20% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link.

SiBone Price Performance

Shares of SIBN stock opened at $14.49 on Tuesday. The company has a debt-to-equity ratio of 0.21, a quick ratio of 7.00 and a current ratio of 8.38. SiBone has a fifty-two week low of $11.70 and a fifty-two week high of $20.05. The firm has a market cap of $625.11 million, a P/E ratio of -25.87 and a beta of 0.83. The business’s 50 day moving average price is $15.70 and its 200-day moving average price is $16.27.

SiBone (NASDAQ:SIBN) last announced its quarterly earnings results on Monday, August 4th. The company reported ($0.14) EPS for the quarter, topping analysts’ consensus estimates of ($0.19) by $0.05. The company had revenue of $48.63 million during the quarter, compared to analyst estimates of $48.12 million. SiBone had a negative return on equity of 14.20% and a negative net margin of 12.83%. SiBone has set its FY 2025 guidance at EPS. On average, equities research analysts anticipate that SiBone will post -0.78 earnings per share for the current year.

Institutional Investors Weigh In On SiBone

A number of hedge funds and other institutional investors have recently bought and sold shares of SIBN. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its holdings in shares of SiBone by 4.5% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 24,426 shares of the company’s stock valued at $343,000 after purchasing an additional 1,053 shares during the last quarter. Rhumbline Advisers increased its position in SiBone by 3.6% during the 1st quarter. Rhumbline Advisers now owns 59,721 shares of the company’s stock valued at $838,000 after buying an additional 2,100 shares in the last quarter. ANTIPODES PARTNERS Ltd purchased a new position in SiBone during the first quarter valued at $34,000. EntryPoint Capital LLC boosted its holdings in SiBone by 21.5% in the first quarter. EntryPoint Capital LLC now owns 14,787 shares of the company’s stock worth $207,000 after acquiring an additional 2,613 shares in the last quarter. Finally, State of Wyoming bought a new stake in SiBone in the second quarter worth $55,000. Hedge funds and other institutional investors own 98.11% of the company’s stock.

Analysts Set New Price Targets

A number of brokerages have recently weighed in on SIBN. Wall Street Zen lowered shares of SiBone from a “buy” rating to a “hold” rating in a research note on Saturday, August 9th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of SiBone in a research report on Saturday, September 27th. Finally, Cantor Fitzgerald set a $25.00 target price on SiBone and gave the stock an “overweight” rating in a research report on Monday, August 11th. Three research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average price target of $23.67.

SiBone Company Profile

SI-BONE, Inc, a medical device company, that operate to solve musculoskeletal disorders of the sacropelvic anatomy in the United States and internationally. It offers proprietary minimally invasive surgical implant system to address sacroiliac joint dysfunction and fusion, adult deformity and degeneration, and pelvic trauma; and implantable bone products.